Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is resistant to virtually all chemo‐ and targeted therapeutic approaches. Epigenetic regulators represent a novel class of drug targets. Among them, BET and HDAC proteins are central regulators of chromatin structure and transcription, and preclinical evidence...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2020-11, Vol.147 (10), p.2847-2861
Hauptverfasser: Zhang, Xin, Zegar, Tim, Weiser, Tim, Hamdan, Feda H., Berger, Benedict‐Tilman, Lucas, Romain, Balourdas, Dimitrios‐IIias, Ladigan, Swetlana, Cheung, Phyllis F., Liffers, Sven‐Thorsten, Trajkovic‐Arsic, Marija, Scheffler, Bjoern, Joerger, Andreas C., Hahn, Stephan A., Johnsen, Steven A., Knapp, Stefan, Siveke, Jens T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!